AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Merck's Q1 Earnings Exceed Estimates, But Tariffs Hit Profit Outlook
ByAinvest
Thursday, Apr 24, 2025 10:52 am ET1min read
Merck lowered its full-year EPS forecast to $8.82-$8.97, down from $8.88-$9.03, due to a $200m tariff hit. The company expects full-year revenue of $64.1-$65.6bn. Q1 earnings beat estimates, driven by oncology portfolio and animal health products, but Keytruda sales fell short. Gardasil sales declined 41% YoY due to weak demand in China and shipment halts. Shares traded down 1.1% at around $78.
Merck & Co. Inc. (MRK) reported its first-quarter 2025 earnings on Thursday, with adjusted earnings per share (EPS) of $2.22, exceeding the consensus estimate of $2.14. The company's quarterly revenue of $15.53 billion also surpassed expectations by $15.31 billion. Despite these strong results, Merck has adjusted its full-year EPS forecast to $8.82-$8.97, down from $8.88-$9.03, citing a $200 million tariff hit [1].The company attributed the tariff costs to levies between the U.S. and China, as well as to a recent licensing agreement with Hengrui Pharma. These tariffs are expected to result in incremental costs of approximately $200 million, primarily impacting the cost of sales and gross margin. Merck has also lowered its full-year sales forecast to between $64.1 billion and $65.6 billion, unchanged from the previous outlook [2].
Keytruda, Merck's best-selling monoclonal antibody, saw a 4% increase in sales to $7.2 billion, but this growth was not enough to offset the 41% decline in Gardasil sales due to weak demand in China and shipment halts. The company's animal health products and oncology portfolio, however, contributed to the quarter's strong performance [3].
Merck's stock traded down 1.1% at around $78.07 following the announcement. The company has invested heavily in the U.S., with a focus on expanding domestic manufacturing and research and development capabilities. It has committed to investing an additional $8 billion in capital investment by 2028 [2].
References:
[1] https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/Merck-Q1-EPS-exceeds-expectations-49705654/
[2] https://www.cnbc.com/2025/04/24/merck-mrk-earnings-report-q1-2025.html
[3] https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet